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Abstract 
Background: In this study, we hypothesized that TB co-infection independently increases the risk of poor treatment 
outcomes in such patients even if they are on antiretroviral therapy (ART). Therefore, this study was aimed at investi-
gating this hypothesis among cohort of adult PLWHs in South West Ethiopia.
Methodology: Cohort study comparing the immunologic and clinical outcomes of 130 HIV/TB co-infected and 520 
only HIV patients starting ART was enrolled. Chi square and student t test were used to compare outcome variables 
and logistic regression was used to assess the effect of TB on treatment failure.
Results: In this study, TB co-infection didn’t increase immunologic failure even in univariate analysis at both 6 [OR, 
1.10 (0.59–1.69), P = 0.85] and 12 months [OR, 1.06 (0.58–1.93), P = 0.89] of ART initiation. However, it increased the 
risk of clinical failure at both 6 [Adjusted Odd Ratio (AOR), 2.90 (1.41–6.09), P = 0.028] and 12 months [AOR, 2.93 
(1.41–6.09), P = 0.004] of ART initiation.
Conclusion: This study showed that TB co-infection didn’t adversely affect the immunologic outcomes, weight and 
hemoglobin responses even though it increased the risk of clinical failure nearly three times. Therefore, beside the 
concern given for TB prevention and treatment, several patient and policy related factors need to be addressed to 
maximally benefit from highly active antiretroviral therapy rollout in resource limited settings.
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Background
Human immunodeficiency virus (HIV) infection sup-
presses immunity and increases the risk of opportunis-
tic infections in which tuberculosis (TB) the leading one 
[1]. There will be about 50 % lifetime risk of developing 
active TB if an individual is HIV positive [2]. Around 
82 % of TB infected people living with HIV (PLWHs) live 
in sub-Saharan Africa [3]. In Ethiopia the proportion of 
HIV/TB co infection in the general population is signifi-
cantly high. Accordingly, it had been reported that most 
of tuberculosis patients were co-infected with HIV with 
recent estimates ranging from 46 to 65 % [4].
According to the WHO Global TB Report 2009 (used 
as background document for the development of this 
study protocol), Ethiopia ranked seventh in the world for 
TB burden and third in Africa in 2008, with an estimated 
TB incidence (all forms) of 378 new cases per 100,000 
persons, 163 new smear positive cases per 100,000 per-
sons, and a prevalence (all forms) of 579 per 100,000 
population. Following an update to estimates for TB 
cases and deaths in the African Region, the most recent 
WHO estimates for Ethiopia are: annual TB incidence 
(including HIV positive) of 261 per 100,000; prevalence 
(including HIV positive) of 394 per 100,000 and mortality 
(excluding HIV) of 35 per 100,000 people [3].
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Antiretroviral therapy (ART) remains one of the best 
strategies in reducing the double trouble imposed by 
HIV/TB co-infection. However, there are many compli-
cations as a result of this co-infection including but not 
limited to combined adverse drug reactions, pill bur-
den, drug–drug interactions and high non-adherence 
rate [5–7]. The cumulative effects of these complications 
could ultimately lead to poor virological, immunological 
and clinical treatment outcomes in these patient groups 
[7–9].
However, there are limited literatures which compared 
outcomes of ART in adult people living with HIV who 
are TB co-infected with that of PLWH without TB co-
infection. Amongst those few literatures available, major-
ity of them are from developed countries [10–12] and 
published works on this issue in resource poor setting 
like Ethiopia is scarce [13–15].
In addition to this, the available evidences are not con-
sistent regarding the differences in outcomes of between 
these two groups of patients when initiated ART. There-
fore, in this study, the hypothesis that says TB co-infec-
tion independently increases the risk of treatment failure 
in PLWHs even if they are on ART and fully adherent to 
such treatment was investigated.
Methods
Study area and period
This study was conducted from December to August 
2012 in Jimma University Specialized Hospital at ART 
clinic, South West Ethiopia. Currently the clinic is serv-
ing a total of 9809 (3519 on ART and 6290 pre-ART) 
PLWHs including those with TB co-infection.
In this clinic, patients have regular follow-up for medi-
cation refill, and to begin ART when the patients meet 
the treatment guideline requirement [16]. CD4 determi-
nation is at first enrollment, during pre-ART, at the time 
of ART initiation and every 6  months as per guideline 
[16].
Study design and population
A retrospective cohort study was conducted using ART 
patient master cards and ART patient registers and 
database. All PLWHs who were on ART at this clinic 
and started such treatment between January 2008 and 
March 2011 were our population. A total of 260 and 1100 
patients with and without TB were enrolled respectively 
during these periods fulfilling the inclusion criteria. Of 
these, we included only adult PLWH (age ≥15 years) who 
were on ART and had at least one follow up clinic visit 
after initiation of ART using simple random sampling. 
In this case, the source population had been categorized 
into two groups and those who fulfilled the inclusion cri-
teria were listed according to their registration number. 
This made the sampling frame for both groups from 
which the required sample size was taken using simple 
random sampling (every other patients record from the 
list). Standard table of sample size for cohort studies was 
used to determine sample size for this study [17].
Accordingly, the final sample size was determined to 
be 650 (PLWH with TB co-infection = 130, and PLWH 
without TB =  520) with 90  % power of the study after 
considering 16  % for possible incompleteness of the 
recordings and 10 % for lost to follow up cases. Data col-
lection was done using a pretested data abstraction for-
mat that was designed for the purpose of this study. It 
was undertaken by well trained pharmacists up on the 
supervision of the principal investigator (Fig. 1).
In this study, immunologic failure has been defined as 
fall of CD4 count to pre-therapy baseline (or below); or 
50 % fall from the on-treatment peak value (if known); or 
Persistent CD4 levels below 100 cells/mm3 [18]. Clinical 
treatment failure means new or recurrent WHO stage 
4 conditions for adults and adolescents. Certain WHO 
clinical stage 3 conditions (e.g. pulmonary TB, severe 
bacterial infections), may be an indication of treatment 
failure [18]. And AIDS defining illnesses in this study 
include conditions listed in the 1993 Expanded AIDS 
Surveillance Case Definition for Adolescents and Adults 
as per center for disease control and prevention (CDC) 
[19].
Data analysis
Statistical package for social sciences (SPSS) version 20.0 
was used for this purpose. All tests were two-tailed and 
P < 0.05 considered significant. Chi square (χ2) test was 
used to compare categorical outcome variables. For con-
tinuous variables, independent sample student t test was 
used. Binary logistic regression was performed to assess 
the effect of TB co-infection on clinical and immunologic 
failure. Categorical variables were reported as frequency 
(%), and continuous variables as mean ± std. error mean 
(standard error of mean).
Ethical consideration
Ethical clearance was obtained from the ethical review 
board of Jimma University College of Public Health and 
Medical Sciences. During data collection, any personally 
identifiable information was not included in the data col-
lection format except the ART unique number of each 
patient to keep confidentiality. No need of securing ver-
bal or written consent as it was secondary data.
Results
Characteristics of the patients at ART initiation
Analysis was made in comparison of two groups of study 
cohorts; PLWHs with HIV/TB co-infection (n  =  130) 
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and with only HIV (n  =  520) at ART initiation. As 
shown in Table  1, the characteristics of patients were 
comparable except that there was significant sex dif-
ference (p  =  0.017). The mean age was 33.6  ±  0.4 and 
33.4  ±  0.8  years respectively for PLWHs without and 
with TB co-infection. The mean values of weight, CD4 
cell count and BMI at ART initiation were all significantly 
higher for PLWHs with only HIV infection. Both groups 
of patients were most commonly prescribed non TDF 
based regimens which accounted for 325 (63.3  %) and 
76 (59.2) of PLWHs without and with TB co-infection 
respectively.
Immunologic failure
In this study, crude analysis indicated that immunologic 
failure was significantly higher in HIV only infected 
patients; 141 (27.1 %) as compared to those with TB co-
infection 29 (22.3 %) at 6 months after initiation of ART 
considering on treatment analysis (p  =  0.043). Similar 
trend had been obtained at 12 months of follow up with 
a failure proportion of 102 (19.6  %) in PLWHs with-
out TB versus 18 (13.8 %) in those with TB co-infection 
(p < 0.001). See Table 2.
Table  3 shows the result of logistic regression analy-
sis in assessing the effect of tuberculosis co-infection on 
immunologic failure rate at 6 and 12  months of follow 
up periods. Accordingly, the presence of TB co-infection 
had been shown to have no significant effect on immuno-
logic failure even in univariate analysis at both six [OR, 
1.10 (0.59–1.69), p  <  0.85] and twelve [OR 1.06 (0.58–
1.93), p = 0.89] months of follow up periods. Rather, the 
effect of other factors like baseline CD4 cell counts of <50 
cells/mm3 [AOR 12.0 (1.26–13.79), p =  0.03], and 101–
200 cells/mm3 [AOR 9.5 (1.08–14.39), p = 0.04] and low 
weight [AOR 0.98 (0.954–0.998), p = 0.03] at ART initia-
tion was seen. In this case, for every 1 kg lower in weight 
at initiation of treatment, patients are 2 % more likely to 
experience immunologic failure (Figs. 2, 3).
However, the risk of immunologic failure decreases as 
the age at ART initiation becomes older and older [AOR 
0.98 (0.95–0.99), P  =  0.04] at 12  months. For this rea-
son, for every 1 year older at initiation of ART, the risk of 
immunologic failure decreases by 2 %.
Clinical failure
Crude analysis showed that after 6  months of ART ini-
tiation, clinical failure was significantly higher in PLWHs 
with TB co-infection; 35.4  % compared to those with 
no TB co-infection; 18.3  % (P  <  0.001). Of those who 
failed clinically, 5.2 % of PLWHs without TB and 10.8 % 
with TB co-infection developed new AIDS defining ill-
nesses (P  =  0.005). Likewise, at 12  months of follow 
up, clinical failure was higher in PLWHs with TB co-
infection by 17.3  % (P  <  0.001). At this time, of those 
Fig. 1 Mean weight measured at baseline (0), 6 and 12 months on ART for PLWHs with TB (bottom line designated as ‘YES’) and without TB (top line 
designated as ‘NO’), South West Ethiopia, 2012
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Table 1 Characteristics of the Patients at ART initiation, South West Ethiopia, 2012
Variables Category TB status p value
No (N = 520) Yes (N = 130)
Age in year, mean ± std. error of mean 33.6 ± 0.4 33.4 ± 0.8 0.850
Gender Male, N (%) 165 (31.7) 56 (43.1) 0.017
Female, N (%) 355 (68.3) 74 (56.9)
Residence Rural, N (%) 125 (24) 35 (26.9) 0.569
Urban, N (%) 395 (76) 95 (73.1)
Marital status Never married N (%) 102 (19.6) 26 (20.0) 0.160
Ever married, N (%) 418 (80.4) 104 (80.0)
Educational level Illiterate, N (%) 102 (19.6) 37 (28.5) 0.168
Primary, N (%) 183 (35.2) 39 (30)
Secondary, N (%) 175 (33.7) 39 (30)
Tertiary, N (%) 60 (11.5) 15 (11.5)
Employment status Unemployed, N (%) 350 (67.3) 91 (70.0) 0.257
Employed, N (%) 170 (33.7) 39 (30.0)
Drug addiction behavior No, N (%) 246 (47.3) 57 (43.8) 0.479
Yes, N (%) 274 (52.7) 73 (56.2)
Weight in kg, mean ± std. error of mean 52.0 ± 0.4 49.1 ± 0.8 0.003
CD4 in cells/mm3, mean ± std. error of mean 153.8 ± 3.8 128.7 ± 9.7 0.006
BMI in kg/m2, mean ± std. error of mean 19.4 ± 0.1 18.2 ± 0.3 <0.001
Hgb mg/dl, mean ± std. error of mean 12.3 ± 0.1 11.03 ± 0.2 <0.001
WHO clinical stage Stage I/II, N (%) 334 (64.2) 0 (0) <0.001
Stage III, N (%) 157 (30.2) 85 (65.4)
Stage IV, N (%) 29 (5.6) 45 (34.6)
ART regimen Non TDF based, N (%) 325 (63.3) 76 (59.2) <0.001
TDF-based, N (%) 196 (37.7) 53 (40.8)
Functional status Working, N (%) 378 (72.7) 51 (38.7) <0.001
Ambulatory, N (%) 127 (24.4) 66 (50.8)
Bed ridden, N (%) 15 (2.9) 13 (10)
Table 2 Outcomes of ART compared based on TB status, South West Ethiopia, 2012
** Compared using Chi square test, * compared using independent sample student t test
ART outcomes Months TB status p value
No (N = 520) Yes (N = 130)
Clinical failure, N (%) 6 95 (18.3) 46 (35.4) <0.001**
12 62 (11.9) 38 (29.2) <0.001**
Immunologic failure, N (%) 6 141 (27.1) 29 (22.3) <0.001**
12 102 (19.6) 18 (13.8) 0.043
AIDS defining illness, N (%) 6 27 (5.2) 14 (10.8) 0.005**
12 20 (3.8) 11 (8.5) <0.001
CD4 cells increase, mean ± std. error of mean 6 146.7 ± 7.2 150.5 ± 14.1 0.827*
12 180.7 ± 8.1 186.1 ± 17.6 0.780
Hemoglobin increase, mean ± std. error of mean 6 1.0 ± 0.1 1.8 ± 0.4 0.028*
12 1.3 ± 0.1 2.0 ± 0.3 0.046
Weight gain in kg, mean ± std. error of mean 6 2.8 ± 0.2 4.4 ± 0.6 0.008*
12 3.9 ± 0.3 5.9 ± 0.8 0.023
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who failed clinically, new AIDS defining illnesses were 
3.8 % in PLWHs without TB and 8.5 % in those with TB 
(P < 0.001) as indicated in Table 2.
As Table  4 shows the presence of TB confection at 
baseline [AOR, 2.90 (1.41–6.09), P  =  0.028] increased 
the risk of clinical failure at 6 months of follow up. Beside 
tuberculosis, factors such as WHO clinical stage III [AOR 
17.83 (7.44–42.73), P < 0.001] and stage IV [AOR 17.06 
(5.12–56.80), P < 0.001] and being ambulatory at baseline 
[AOR 1.86 (1.049–3.286), P = 0.034] were the predictors 
of clinical failure at 6  months of follow up. Similarly, at 
12  months, the presence of TB co-infection [AOR 2.93 
(1.412–6.094), P = 0.004] continued to increase the risk 
of clinical failure. Other baseline variables such as work-
ing parttime [AOR, 6.07 (1.63–22.65), P  =  0.007], hav-
ing drug addiction behavior [AOR 1.76 (1.02–3.03), 
P  =  0.04], WHO stage III [AOR 6.98 (3.03–16.08), 
P  <  0.001] and WHO stage IV [AOR 6.88 (2.09–22.64), 
P = 0.002] were shown to be independent predictors of 
clinical failure at 12 months of ART initiation in addition 
to tuberculosis co-infection.
CD4 cells, hemoglobin and weight responses 
on antiretroviral regimens
The mean gains in CD4 cells at 6  months of follow up 
periods was 150.5 ± 14.1 cells/mm3 in PLWHs with TB 
co-infection and 146.7  ±  7.2 cells/mm3 in those with-
out TB co-infection. At 12 months it was 180.7 ± 8.1 in 
PLWHs with TB co-infection and 186.1 ± 17.6 cells/mm3 
in those without TB co-infection. However, these differ-
ences were statistically insignificant at both 6  months 
(P = 0.83) and 12 months (P = 0.78) of ART initiation.
However, the mean hemoglobin gains were significantly 
greater in PLWHs with TB co-infection; 1.0 ± 0.1 versus 
1.8 ± 0.4 g/dl at 6 months (P = 0.028) and 1.3 ± 0.1 ver-
sus 2.0 ± 0.3 g/dl at 12 months (p = 0.046). Similarly, the 
mean weight gains was significantly greater in PLWHs 
with TB co-infection; 2.8  ±  0.2 versus 4.4  ±  0.6  kg at 
6 months (p = 0.008) and 3.9 ± 0.3 versus 5.9 ± 0.8 kg at 
12 months (p = 0.023). See Table 2 for better illustration 
of these results.
Discussion
In this study, the difference in outcomes of first line 
antiretroviral regimens between two groups of patients: 
PLWHs with and without TB co-infection during the 
initiation of ART were compared. In addition, the effect 
of tuberculosis on these outcome variables was assessed 
and discussed accordingly.
In this study, when the mean increases in CD4 cells 
count were compared the difference was not signifi-
cant for both groups of PLWHs in contrary to what had 
been reported as starting ART, particularly early dur-
ing TB treatment, could jeopardize adherence to treat-
ment and hence worsening of the immune response [20]. 
Hung et al. [10], Sharma and colleagues [21], Sinha et al. 
[12] and Lipman et al. [11] also showed similar findings. 
According to one study the additional increment in CD4 
count in patients with co-infection following treatment 
suggest that CD4 suppression at the onset of TB may be 
the direct result of mycobacterium growth and inflam-
mation as well as interaction between TB and HIV in 
addition to the effect of HIV alone [21]. Hence, up on 
appropriate treatment for both diseases, greater degree of 
Table 3 Logistic regression model for  assessing the effect of TB co-infection on  immunologic failure, December 2011–
August 2012, JUSH, Ethiopia
Logistic regression Follow up time in months
At 6 months of ART initiation At 12 months of ART initiation
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95 % CI) P AOR (95 % CI) P AOR (95 % CI) P AOR (95 % CI) P
Variables
 TB status
  Absent Reference – Reference Reference – Reference –
  Present 1.10 (0.59–1.69) 0.985 0.96 (0.56–3.46) 0.540 1.06 (0.58–1.93) 0.839 1.04 (0.46–1.89) 0.740
 Age in years 0.98 (0.96–1.01) 0.100 0.76 (0.75–2.23) 0.062 0.97 (0.95–0.99) 0.012 0.98 (0.95–0.99) 0.049
 Weight in kg 0.97 (0.95–0.99) 0.011 0.98 (0.95–0.99) 0.030 0.99 (0.96–1.01) 0.218 0.37 (0.089–3.45) 0.347
CD4 count category in cells/mm3
 <50 14.2 (1.52–16.42) 0.020 12.0 (1.26–13.79) 0.031 24.67 (1.25–32.53) 0.005 19.97 (2.09–34.52) 0.009
 50–100 10.4 (1.45–14.53) 0.003 9.8 (1.26–12.80) 0.044 13.43 (1.52–18.63) 0.019 12.28 (1.37–14.09) 0.025
 101–200 9.6 (1.09–13.87) 0.041 9.50 (1.08–14.39) 0.043 15.52 (1.82–26.48) 0.012 14.39 (1.66–23.49) 0.015
 >200 Reference – Reference – Reference – Reference –
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CD4 cells upsurge can occur. Moreover, a study done in 
London showed that study participants in the EFV group 
had a CD4 count increase of on average 26 cells/mm3 
higher than those in the NVP group [22]. As majority of 
study participants with TB co-infection in this study were 
on EFV based regimens, they could recover their immu-
nity faster as a result.
TB co infection at initiation of ART, in this study, was 
found to have no impact on immunologic failure in both 
univariate and multivariate analysis. This is similar to a 
3 years pediatric ART outcome study in Ethiopia [23] and 
a 4 years adult ART outcome study in Mozambique [22]. 
It has been further demonstrated that concurrent TB co-
infection had not increased the risk of immunologic fail-
ure in South Africa [24].
In the present study, clinical failure and hence HIV 
progression was also determined and compared between 
PLWHs with and without TB co-infection. Accordingly, 
it was observed to be significantly higher in PLWHs with 
TB co-infection. In Taiwan, similar finding was reported 
[3]. This could be due to the fact that PLWHs with TB 
co-infection had additionally greater proportion of other 
AIDS defining conditions when initiating ART. This had 
been shown in one study conducted in united state as 
well [25].
Furthermore, studies are reporting that drug abuse 
such as alcohol after contracting HIV seems to accelerate 
disease progression through a direct effect on CD4+ cells 
and also indirectly by increasing medication non-adher-
ence rate [26, 27]. Therefore, as larger number (but not 
statistically significant) of such patients found in PLWHs 
with TB co infection group in this study, it might contrib-
ute to the significantly worse HIV progression in the later 
group of patients. The result of our multivariate logistic 
regression analysis also confirmed that tuberculosis co-
infection increased the risk of clinical failure and also 
HIV progression several folds.
Studies are claiming that hemoglobin level and weight 
can be utilized as important tools for monitoring out-
comes of antiretroviral therapy in resource limited set-
tings like Ethiopia [28, 29]. We also compared these 
variables between PLWHs with and without TB co infec-
tion who were on treatment in this study.
Accordingly, the difference in mean values of weight 
gain was significant for the two groups of PLWHs. It 
was observed that patients without TB, in this study, had 
Fig. 2 Mean CD4 cells count measured at baseline (0), 6 and 12 months on ART for cohorts with TB (bottom line designated as ‘YES’) and without TB 
(top line designated as ‘NO’), South West Ethiopia, 2012
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greater weights at baseline. Nevertheless, the amount of 
change with time was significantly higher in HIV/TB co 
infected patients. This finding was in agreement with that 
of study conducted in India [21]. This could be due to the 
fact that in more sick individuals, such parameter has to 
increase faster during treatment (both anti TB and ART) 
as they need to attain medically required states faster. 
It could occur as a result of improvement in nutritional 
status after initiation of HAART and TB therapy [30]. 
Moreover, this weight gain is presumed to be caused by 
the suppression of viral replication in HIV-infected indi-
viduals on HAART [31].
The present study also compared the average increase 
in hemoglobin for the two groups of patients. Studies 
showed that pulmonary tuberculosis as well as other 
AIDS defining opportunistic infections are associ-
ated with a higher risk of anemia among HIV-positive 
patients [32, 33]. Regardless of this fact, the increase 
in hemoglobin on ART in this study was significantly 
greater for PLWHs with TB confection even if the 
later has lower hemoglobin level at the initiation of 
treatment.
Limitations
Limitations of the present study primarily relate to the 
fact that analyses were based on routinely collected data, 
which were incomplete for certain baseline and follow-up 
clinical characteristics. Another limitation is that there 
could be misclassification bias as it is not easy to diag-
nosis TB in HIV positive patients. As a result, HIV/TB 
co-infected patients may be treated only for HIV and also 
only HIV infected patients may be treated wrongly for 
TB as well.
Conclusion
This study showed that TB co-infection didn’t signifi-
cantly increase the risk of immunologic failure. Weight 
and hemoglobin responses were even better in co-
infected patients. However, these patients were more 
likely to experience clinical failure and that the co-infec-
tion roughly triples the risk of clinical failure. In general, 
for better outcomes of ART rollouts in Ethiopia the fol-
lowing points need to be addressed. Primarily, there 
should be improved strategies to ensure patients present 
early to health facilities. In addition, earlier nutritional 
Fig. 3 Mean hemoglobin level measured at baseline (0), 6 and 12 months on ART for cohorts with TB (bottom line designated as ‘YES’) and without 
TB (top line designated as ‘NO’), South West Ethiopia, 2012
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intervention, prevention of TB, establishing dedicated 
adolescent and youth services at ART clinics and address-
ing drug addiction behavior of individuals on ART could 
improve ART outcomes.
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